Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Prothena Corporation plcNASDAQ: PRTA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $918K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $30.8M.

Context

  • Cost of revenue amounted to 38.2% of revenue in FY2025, up 38.2 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $918K or moves back toward the trailing-twelve-month quarterly average of $7.7M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$918K-2.5% QoQ
Last fiscal yearDec 2025
$3.7M— YoY
LTMMar 2026
$30.8M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
3.7M USD
Year-over-year change
—

Cost of Revenue vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 53.2% of revenue for PRTA, versus a peer median of 32.3%.
PRTA Competitors
Cost of Revenue for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$3.21B USD+17.0%+8.3%32.3%
PRTAProthena Corporation plcLTM Mar 2026$30.8M USD——53.2%
DNLIDenali Therapeutics Inc.LTM Jun 2026$5.8M USD——161.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$5.01M USD———
ANNXAnnexon, Inc.LTM Mar 2026$1.9M USD———
CGTXCognition Therapeutics, Inc.LTM Mar 2026$129K USD———
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$46K USD+4.5%——
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 USD———
PMNProMIS Neurosciences, Inc.LTM Jun 2026$0 USD———
Peer median (excluding PRTA) —+10.8%+8.3%32.3%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.